ProCE Banner Series

Are You Ready to Elevate Your Knowledge? Integrating AAD Guideline Updates to Optimize Patient Care in Atopic Dermatitis

Moderate to severe atopic dermatitis is a chronic condition characterized by unpredictable, relapsing flares. Fortunately, the treatment landscape has expanded greatly over the last several years, offering a variety of safe and effective options. In this session, expert faculty will review the recent American Academy of Dermatology guidance on incorporating systemic therapies into their practice to improve patient and disease related outcomes.  

CME/CE credits and faculty are provided by Practicing Clinicians Exchange. You must be a registered attendee of the Elevate-Derm East Conference to attend in person. Visit  elevate-derm.com/east-summer-2024 for more information.

  AAPA
  | ANCC
Who Should Attend

This program is intended for dermatology NPs and PAs and other NPs and PAs who care for patients with moderate to severe atopic dermatitis.

All Events

Are You Ready to Elevate Your Knowledge? Integrating AAD Guideline Updates to Optimize Patient Care in Atopic Dermatitis

Upcoming Events

July

26

2024

6:30 PM - 7:45 PM Eastern Time (ET)

In-person

The Westin Boston Copley Place, 10 Huntington Avenue, Boston, Massachusetts 02216

6:45 PM - 7:45 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Victoria Garcia-Albea, NP, DCNP

Lahey Dermatology
Director, Lahey Dermatology Nurse Practitioner Training Program
Burlington, Massachusetts

ProCE Banner Faculty
Benjamin Ungar, MD

Assistant Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York

Topics

Atopic dermatitis 

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Atopic Dermatitis.

Target Audience
This program is intended for dermatology NPs and PAs and other NPs and PAs who care for patients with moderate to severe atopic dermatitis.

Learning Objectives
Upon completion of this activity, participants should be able to:

  •  Implement the latest guideline recommendations for systemic therapies to treatment decisions for patients with moderate to severe AD
  • Choose appropriate patient candidates for recommended systemic therapies for moderate to severe AD
  • Create treatment plans based on the newest guidelines, available data, and expert guidance on systemic therapies for moderate to severe AD

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE).

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.